Form 4: Apellis CSO Sells Shares for Tax Obligations

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, sold 2,277 shares of common stock to satisfy tax withholding requirements on recently vested Restricted Stock Units.

Summary

• Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction on January 13, 2026.
• The transaction involved the sale of 2,277 shares of common stock.
• The shares were sold at a price of $22.1872 per share.
• The sale was conducted to cover tax withholding obligations related to Restricted Stock Units (RSUs) that were released on January 12, 2026.
• Following this transaction, Deschatelets beneficially owns 1,158,219 shares of Apellis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale of shares to cover tax withholding on vested Restricted Stock Units, which is a neutral event and does not reflect positively or negatively on the company's performance or management's outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a sale of shares to cover tax obligations on vested equity. Such transactions are common across all industries, particularly in publicly traded companies where executive compensation often includes equity awards.

Comparison to Industry Standards

• Sales of shares to cover tax withholding on vested equity awards are a standard practice for executives across various industries, including biotechnology and pharmaceuticals, and are generally considered non-discretionary transactions.
• This type of transaction is not typically indicative of a change in management's sentiment towards the company's prospects, unlike open market sales for personal liquidity.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes, not a discretionary sale indicating a change in insider sentiment.

Key Dates

Keywords

APLS, Apellis Pharmaceuticals, Form 4, Insider Transaction, Stock Sale, RSU, Tax Withholding, Pascal Deschatelets, Chief Scientific Officer